{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:20:25Z","timestamp":1759033225522},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T00:00:00Z","timestamp":1307059200000},"content-version":"vor","delay-in-days":63,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Olanzapine augmentation of fluoxetine, a selective serotonin reuptake inhibitor, is an effective augmentation therapy for treatment\u2010resistant depression (TRD). However, studies of olanzapine augmentation of other antidepressants are few. We investigated the efficacy and safety of olanzapine augmentation of milnacipran, a serotonin\u2013norepinephrine reuptake inhibitor, for TRD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study covered patients with stage 2 TRD, defined by Thase and Rush. Olanzapine was added to milnacipran, and its dosage was adjusted according to each patient. Previous treatments were continued, but no new treatments were allowed. Response was measured using Hamilton Depression Rating Scale (HAMD) and Clinical Global Impression at weeks\u20090, 1, 2, 3, 4, and 8.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eleven patients aged 53.2\u2009\u00b1\u200924.0\u2009years received olanzapine at 5.0\u2009\u00b1\u20091.9\u2009mg\/day with milnacipran. HAMD and Clinical Global Impression scores improved significantly from baseline to endpoint. This improvement occurred in week\u20091. At endpoint, seven of 11 (64%) were responders on HAMD (\u226550% reduction). Four patients (36%) discontinued the trial because of no efficacy. No severe adverse effect occurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Olanzapine augmentation of milnacipran for stage 2 TRD might be effective and well tolerated. However, our study is open label and uncontrolled. Therefore, a double\u2010blind controlled trial is necessary to confirm our results. Copyright \u00a9 2011 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.1197","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T12:48:16Z","timestamp":1307105296000},"page":"237-241","source":"Crossref","is-referenced-by-count":5,"title":["Olanzapine augmentation of milnacipran for stage 2 treatment\u2010resistant major depression: an open study"],"prefix":"10.1002","volume":"26","author":[{"given":"Shuken","family":"Boku","sequence":"first","affiliation":[{"name":"Department of Psychiatry Hokkaido University Graduate School of Medicine  Sapporo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Hokkaido University Graduate School of Medicine  Sapporo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Honma","sequence":"additional","affiliation":[{"name":"Department of Psychiatry National Hospital Organization Obihiro Hospital  Obihiro Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigehiro","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Psychiatry National Hospital Organization Obihiro Hospital  Obihiro Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Hokkaido University Graduate School of Medicine  Sapporo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Hokkaido University Graduate School of Medicine  Sapporo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,6,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.05.004"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0193-953X(05)70293-8"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n1118"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622970209150599"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(95)01341-5"},{"key":"e_1_2_7_7_1","first-page":"252","article-title":"The therapeutic role of 5\u2010HT1A and 5\u2010HT2A receptors in depression","volume":"29","author":"Celada P","year":"2004","journal-title":"J Psychiatry Neurosci"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.9058se1c.04gry"},{"key":"e_1_2_7_9_1","first-page":"214","article-title":"Progress in treatment\u2010resistant and treatment\u2010refractory depression: we still have a long way to go","volume":"24","author":"Fawcett J","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2007.06.002"},{"key":"e_1_2_7_11_1","first-page":"13","article-title":"Use of atypical antipsychotics in refractory depression and anxiety","volume":"66","author":"Nemeroff CB","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"e_1_2_7_12_1","first-page":"39","article-title":"Treatment\u2010resistant depression: definition and treatment approaches","volume":"51","author":"Nierenberg AA","year":"1990","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.4.796"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(98)00040-6"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200206001-00004"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0327(82)90002-7"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.1.131"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.181.4.284"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.914"},{"key":"e_1_2_7_21_1","first-page":"1081","volume-title":"Psychopharmacology: The Fourth Generation of Progress","author":"Thase ME","year":"1995"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800320058007"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050834"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.1197","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.1197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T18:24:30Z","timestamp":1700591070000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.1197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1002\/hup.1197"],"URL":"https:\/\/doi.org\/10.1002\/hup.1197","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}